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Timing of antenatal care and ART initiation 
in HIV-infected pregnant women before 
and after introduction of NIMART
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In this review of routinely collected data from five community health centres in the Johannesburg Health District, we assess 
timing of antenatal care and antiretroviral therapy (ART) initiation in HIV-infected pregnant women before and after the 
introduction of nurse-initiated management of ART in antenatal clinics. There are important lessons to be learnt as we reflect 
on the South African prevention of mother-to-child transmission of HIV programme. 
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It is widely acknowledged that the highest 
risk of mother-to-child transmission (MTCT) 
of HIV is in HIV-infected women with low 
CD4+ counts, who are eligible for antiretroviral 
therapy (ART).[1] Timely initiation of ART in 
this group is critical to decreasing paediatric HIV infection 
and HIV-related maternal morbidity and mortality.[2,3] ART 
initiation in pregnancy is also associated with better maternal 
immunological and virological outcomes compared with 
starting ART after pregnancy.[4] 
Prior to the current prevention of MTCT (PMTCT) 
guidelines, criteria for ART initiation in pregnant women 
were based on a CD4+ count of ≤350 cells/µl, or World Health 
Organization (WHO) stage 3 or 4 disease regardless of CD4+ 
count.[5] Reflecting on the history of the PMTCT programme in 
South Africa, two of the main early challenges to initiating ART 
in pregnancy were that HIV treatment sites were physically 
separate from antenatal clinics and ART initiation was largely 
physician led.[6] This led to delays in referral and initiating 
treatment, and as a result, a significant proportion of ART-
eligible pregnant women would go through pregnancy with-
out starting treatment.[7] Nurse-initiated and managed ART 
(NIMART) in antenatal clinics was introduced to address these 
challenges, supported by evidence that integration of ART with 
antenatal care decreases time to initiation and increases the 
proportion of pregnant women initiated.[8-10] Pregnant women 
need to access antenatal care early for timeous treatment 
initiation. 
This retrospective review of routinely collected data assesses 
timing of antenatal care and ART initiation in HIV-infected, 
eligible pregnant women presenting to five community health 
centres in the Johannesburg Health District. 
Method
Time to initiation in pregnant women who presented prior to 
the introduction of NIMART was compared with those who 
presented after. Between October 2010 and March 2012, a total 
of 1 436 ART-eligible pregnant women were identified. 
The study was approved by the University of Cape Town’s 
Human Research Ethics Committee, and by the Gauteng 
Province office for policy, planning and research. 
Results
Characteristics of the women are presented in Table 1. The mean 
gestational age when accessing antenatal care was 19.2 weeks 
(standard deviation (SD) of 6.6), and the mean gestational age at 
ART initiation was 24.6 weeks (SD 6.2). There was no significant 
reduction in time to initiation after the introduction of NIMART. 
Overall, the median time to initiation prior to the introduction 
of NIMART was 3.4 weeks (interquartile range (IQR) 2.0 - 5.9) 
whereas after the introduction of NIMART, it was 3.0 weeks (IQR 
1.4 - 5.4). Assessing data from individual clinics, there was evi -
dence of an increase in time to starting ART in some facilities. 
However, overall there was an increase in the proportion of eli-
gible pregnant women who started ART after the introduction of 
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available for 61.8% of the women, namely 881 live births, 1 neonatal death, 
4 stillbirths and 2 miscarriages. Of the 881 in fants tested at ~6 weeks of 
age, only two (0.2%) were HIV-infected. 
Discussion
The data provided an interesting reflection on the PMTCT programme. 
While pregnant women in the review accessed antenatal care relatively 
late, in the second trimester, there were no lengthy delays in initiating 
ART in patients who reached the HIV management sites, even prior 
to the introduction of NIMART in antenatal clinics. Despite several 
challenges in the antiretroviral (ARV) roll-out in the past few years, the 
data showed that there were pockets of excellence. In the facilities where 
the intervention increased time to initiation, there are several possible 
reasons for this: there could have been a shortage of skilled and properly 
trained staff to manage ART-eligible pregnant women in the antenatal 
clinics; and during the early stages of the introduction of NIMART, 
antenatal clinics were only able to initiate treatment on select days.
Conclusion
While the updated PMTCT guidelines recommend starting all HIV-
infected pregnant women on ART at the first antenatal visit, to reduce 
delays in initiating therapy, focus needs to shift from quantity to quality. 
As the number of patients on treatment increases, clinicians need to 
ensure that they provide high-quality services with appropriate clinical 
and laboratory monitoring, and long-term retention of patients in care.
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Table 1. Baseline characteristics and timing of ART initiation 
Facilities
 A B C D E
Baseline CD4+ count (cells/µl)
Mean (±SD) 211 (±85) 223 (±86) 215 (±87) 240 (±112) 228 (±81)
Median (IQR) 214 (151 - 284) 234 (147 - 299) 225 (152 - 286) 245 (174 - 299) 235 (169 - 296)
Range 15 - 344 27 - 350 23 - 350 25 - 650 45 - 351
Gestational age at 1st antenatal visit (weeks)
Mean (±SD) 20.7 (±6.4) 17.4 (±6.2) 19.9 (±5.9) 18.1 (±6.9) 19.5 (±6.9)
Median (IQR) 20 (16 - 24) 18 (12 - 20) 20 (16 - 24) 16 (12 - 24) 20 (15 - 24)
Range 8 - 36 4 - 30 8 - 32 4 - 36 5 - 36
Gestational age at ART initiation (weeks)
Mean (±SD) 25.4 (±6.4) 22.0 (±5.8) 24.3 (±5.5) 24.6 (±6.6) 25.1 (±6.3)
Median (IQR) 25 (21 - 30) 21 (18 - 27) 25 (20 - 28) 24 (20 - 30) 25 (21 - 30)
Range 12 - 37 8 - 34 14 - 36 11 - 39 10 - 38
Time to initiation prior to NIMART 
(weeks)
Mean (±SD) 1.6 (±0.5) 4.0 (±2.7) 5.5 (±2.5) 2.6 (±0.8) 3.3 (±1.8)
Median (IQR) 1.9 (1.3 - 2.3) 3.1 (2.0 - 5.1) 5.6 (1.7 - 7.0) 2.4 (1.9 - 3.2) 2.8 (1.9 - 5.1)
Range 1.0 - 2.3 0.9 - 10.6 1.1 - 12.6 1.6 - 4.0 1.3 - 5.9
Time to initiation after NIMART (weeks)
Mean (±SD) 2.0 (±1.9) 4.4 (±3.3) 3.8 (±3.5) 5.7 (±3.8) 6.6 (±3.9)
Median (IQR) 1.3 (1.0 - 2.3) 3.7 (2.4 - 5.1) 2.1 (1.4 - 4.9) 4.1 (3.0 - 8.1) 6.0 (4.0 - 8.8)
Range 0 - 9.7 0 - 18.9 0.7 - 15.7 0.7 - 18.4 0.6 - 18.7
ART = antiretroviral therapy; SD = standard deviation; IQR = interquartile range; NIMART = nurse-initiated management of antiretroviral therapy.
